TrialBritish journal of haematology2022

Obinutuzumab as consolidation after chemo-immunotherapy: Results of the UK National Cancer Research Institute phase II/III GALACTIC trial.

Talha Munir et al.PubMed ↗Publisher ↗

No numbers read from the abstract.